Annika Espander Jansson has 25 years’ experience as an analyst and investor, as well as from executive positions within the financial markets and the pharmaceutical industry. She is the founder of Asperia AB and has been the CEO since June 2013. Annika Espander Jansson was born in 1964 and holds a BSc in Chemistry from Uppsala University (Sweden)/University of Michigan, Ann Arbor (US) and an MBA in International Business Management from Uppsala University. From 2010 to 2013, she was Chief of Private Banking at Handelsbanken and also Chairman of the Board of SHB Luxembourg; she has previously held executive positions at, among other companies, Catella Healthcare/Esperio AB in Stockholm and at Enskilda Securities. Annika Espander Jansson is a member of the Board of Asperia AB, Esperio AB and Symphogen AS, and she has previous Board experience from Biotage AB, Probi AB, Stille AB, Cellartis AB and SFF (Sveriges Finansanalytikers Förening) among other companies.
Johan Malmqvist has extensive experience from the medical technology industry. Johan Malmqvist was born in 1961 and holds a BA from Stockholm School of Economics. From 1997 to 2015, he was president and CEO of Getinge AB. Before that, he held various positions within the Getinge group and before joining Getinge in 1990, Johan Malmqvist held several positions within the Electrolux group. From 1997 to 2007, Johan Malmqvist was a member of the Board of Getinge AB.
In accordance with the Nomination Committee’s proposal, the number of Board members will thus be nine.
The Nomination Committee’s complete proposal for resolution at the Annual General Meeting, to be held on September 1, 2015, will be available on the company’s website and will be published in the notice of the Annual General Meeting.
The Nomination Committee, prior to the 2015 Annual General Meeting, comprises the following members: Laurent Leksell (Chairman), appointed by the Leksell family for the family’s direct and indirect holdings and in his capacity as Chairman of the Board, Åsa Nisell, appointed by Swedbank Robur Funds, Jens Barnevik, appointed by Didner & Gerge Funds, Anders Oscarsson, appointed by AMF and AMF Funds, and Ossian Ekdahl, appointed by Första AP-fonden. Caroline Leksell Cooke has been co-opted to the Nomination Committee.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.